OmniAb’s xPloration Platform: Unleashing the Power of AI in Antibody Engineering

Published | Modified May 15, 2024
CSIMarket Newsroom | CSIMarket.com

OmniAb Revolutionizes Antibody Engineering with Innovative xPloration Platform

Emeryville, Calif. - OmniAb, Inc. made a significant impact at the 20th Annual PEGS Boston Summit by unveiling its groundbreaking high-throughput single B-cell screening platform called xPloration. This innovative technology, which incorporates machine learning and Artificial Intelligence (AI), has the potential to revolutionize the field of protein and antibody engineering.

During the conference, OmniAb presented an overview of xPloration in a session

Source for this article: Based on Omniab Inc ’s official statement

For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .

Comments

Comments are available to active subscribers. Subscribe or Log in.

Get the full CSIMarket dataset: Subscribe API License